OR WAIT null SECS
Agnes Shanley is senior editor of Pharmaceutical Technology.
A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?
Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.
eBook: Regulatory Sourcebook, March 2021
When referring to this article, please cite it as: A. Shanley, "Can FDA Reinvent Inspections, BioPharm International Regulatory Sourcebook eBook (March 2021).